Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory/Relapsing Solid Tumors

Next Previous
Trial Profile

Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory/Relapsing Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Nivolumab (Primary) ; Vinblastine (Primary)
  • Indications Ependymoma; Ewing's sarcoma; Glioma; Lymphoma; Neuroblastoma; Rhabdomyosarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Metro-PD1

Most Recent Events

  • 29 May 2026 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026).
  • 29 Apr 2025 Planned End Date changed from 1 Jan 2028 to 1 Jan 2027.
  • 24 Jun 2024 This trial has been Discontinued in Belgium, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top